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July 19, 2011:441–4(5–7). Because benefits of CRT-D are mainly linked to reverse
remodeling, an ischemic population will probably have a worse
response and, thus, a poorer outcome. In patients with previous
myocardial infarction, global scar burden and extent of viable
myocardium directly correlate with remodeling after CRT (8,9).
oreover, the location of prior infarction is also important to the
esponse. Lateral lead placement improves reverse remodeling and
unctional capacity compared with other locations (10); postero-
ateral scar, independently from the presence of LV dyssynchrony,
as a negative impact on the response to CRT (11,12). A greater
roportion of women in the MADIT-CRT (Multicenter Auto-
atic Defibrillator Implantation Trial–Cardiac Resynchronization
herapy) had a left bundle branch block, which is a predictor of
esponse to cardiac resynchronization therapy.
In conclusion, we recognize the effectiveness of CRT-D also in
elatively asymptomatic heart failure patients with a low ejection
raction and wide QRS complex, as previously demonstrated by the
ADIT-CRT trial (13), but we suggest the use of a matched
ohort of patients to support the hypothesis that CRT-D is more
ffective in women to avoid confounding bias.
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Reply
We thank Dr. Durante and colleagues for their interest in our
paper (1) and their comments. Ischemic cardiomyopathy remains
the most common etiology of systolic heart failure (2). In the
MADIT-CRT (Multicenter Automatic Defibrillator Implanta-
tion Trial–Cardiac Resynchronization Therapy) (3), 55% of pa-
tients had ischemic cardiomyopathy and 45% had nonischemic
cardiomyopathy (NICM). This substrate distribution is similar to
other contemporary early stage heart failure trials (4,5). The RAFT
(Resynchronization/Defibrillation for Ambulatory Heart Failure
Trial) recently showed that patients with ischemic or nonischemic
causes of heart failure had a similar benefit from implantable
cardioverter-defibrillator–cardiac resynchronization therapy in
early-stage heart failure (6).
For the sex substudy in the MADIT-CRT trial, we found 72%
of the women had NICM as compared with 36% of men.
Examining the NICM subgroup further, we found women had a
significant reduction of the primary endpoint of heart failure and
death (70%) or heart failure alone (69%), with significant interac-
tion p values compared with men after receiving cardiac resynchro-
nization therapy defibrillators (CRT-D). No prior study has
demonstrated a significantly greater benefit from device therapy for
women than men with regard to mortality or cardiac-related
outcomes in an overall study population or by disease etiology.
It is possible that among patients with heart disease, the risk of
heart failure is greater for women than for men, resulting in a
greater benefit from preventive CRT-D therapy in women.
Women might also have more dyssynchrony with equivalent QRS
width compared with men. Of note, left bundle branch block
(LBBB) was present in 70% of the MADIT-CRT patients, with
31% of the females having LBBB in this subset. Even within the
LBBB subset, women had a significantly greater benefit from
CRT-D than men after adjustment for relevant covariates (7).
The findings from the MADIT-CRT trial with regard to the
enhanced benefit in women when compared with men are quite
strong. We doubt that a substrate matched trial of men and women
with early-stage heart failure receiving CRT-D with equivalent
rates of LBBB would further advance our knowledge in this area.
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